Breast cancer risk for Korean women with germline mutations in BRCA1 and BRCA2

[1]  D. Easton,et al.  Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations , 2013, Journal of Medical Genetics.

[2]  W. Han,et al.  Korean Risk Assessment Model for Breast Cancer Risk Prediction , 2013, PloS one.

[3]  W. Chung,et al.  A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[4]  J. Lee,et al.  Accuracy of BRCA1/2 mutation prediction models in Korean breast cancer patients , 2012, Breast Cancer Research and Treatment.

[5]  Mads Thomassen,et al.  Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers , 2012, Breast Cancer Research.

[6]  D. Noh,et al.  The Korean Hereditary Breast Cancer (KOHBRA) study: protocols and interim report. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

[7]  P. Radice,et al.  The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers , 2011, Breast Cancer Research and Treatment.

[8]  B. Bonanni,et al.  Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. , 2010, European journal of cancer.

[9]  M. Urioste,et al.  The Average Cumulative Risks of Breast and Ovarian Cancer for Carriers of Mutations in BRCA1 and BRCA2 Attending Genetic Counseling Units in Spain , 2008, Clinical Cancer Research.

[10]  F. Schmidt.  Meta-Analysis , 2008 .

[11]  Giovanni Parmigiani,et al.  Meta-analysis of BRCA1 and BRCA2 penetrance. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Friedman,et al.  Cancer risks among BRCA1 and BRCA2 mutation carriers , 2007, British Journal of Cancer.

[13]  K. Offit,et al.  Prevention and management of hereditary breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Bonaïti‐pellié,et al.  Estimating penetrance from family data using a retrospective likelihood when ascertainment depends on genotype and age of onset , 2004, Genetic epidemiology.

[15]  M. King,et al.  Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.

[16]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[17]  Argyrios Ziogas,et al.  Validation of family history data in cancer family registries. , 2003, American journal of preventive medicine.

[18]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[19]  C. Bonaïti‐pellié,et al.  Hereditary non-polyposis colorectal cancer: current risks of colorectal cancer largely overestimated , 2002, Journal of medical genetics.

[20]  Ashok R Venkitaraman,et al.  Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.

[21]  C B Begg,et al.  The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  D. Easton,et al.  Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. , 2001, American journal of human genetics.

[23]  P. Pharoah,et al.  Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases , 2000, British Journal of Cancer.

[24]  G. Giles,et al.  Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[25]  W. Foulkes,et al.  Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. , 1999, Journal of the National Cancer Institute.

[26]  J. Struewing,et al.  Population-based study of risk of breast cancer in carriers of BRCA2 mutation , 1998, The Lancet.

[27]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[28]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[29]  Julian Peto,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.

[30]  N. Boyd,et al.  Accuracy of family cancer history in breast cancer patients , 1994, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[31]  W J Ewens,et al.  A resolution of the ascertainment sampling problem. II. Generalizations and numerical results. , 1988, American journal of human genetics.

[32]  W J Ewens,et al.  A resolution of the ascertainment sampling problem. I. Theory. , 1986, Theoretical population biology.

[33]  M. Urioste,et al.  Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers , 2009, Breast Cancer Research and Treatment.

[34]  D. Bishop,et al.  Breast and Ovarian Cancer Incidence in BRCA I -Mutation Carriers , 2007 .

[35]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[36]  K. Lange,et al.  Programs for pedigree analysis: Mendel, Fisher, and dGene , 1988, Genetic epidemiology.